Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Giuseppe Murdaca
 -- 3180 2023-08-01 08:12:23 |
2 format change
Peter Tang
 + 1 word(s) 3181 2023-08-01 08:19:38 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Murdaca, G.; Allegra, A.; Paladin, F.; Calapai, F.; Musolino, C.; Gangemi, S. Alarmins in Pathogenesis and Progression of Multiple Myeloma. Encyclopedia. Available online: https://encyclopedia.pub/entry/47469 (accessed on 18 May 2024).
Murdaca G, Allegra A, Paladin F, Calapai F, Musolino C, Gangemi S. Alarmins in Pathogenesis and Progression of Multiple Myeloma. Encyclopedia. Available at: https://encyclopedia.pub/entry/47469. Accessed May 18, 2024.
Murdaca, Giuseppe, Alessandro Allegra, Francesca Paladin, Fabrizio Calapai, Caterina Musolino, Sebastiano Gangemi. "Alarmins in Pathogenesis and Progression of Multiple Myeloma" Encyclopedia, https://encyclopedia.pub/entry/47469 (accessed May 18, 2024).
Murdaca, G., Allegra, A., Paladin, F., Calapai, F., Musolino, C., & Gangemi, S. (2023, August 01). Alarmins in Pathogenesis and Progression of Multiple Myeloma. In Encyclopedia. https://encyclopedia.pub/entry/47469
Murdaca, Giuseppe, et al. "Alarmins in Pathogenesis and Progression of Multiple Myeloma." Encyclopedia. Web. 01 August, 2023.
Alarmins in Pathogenesis and Progression of Multiple Myeloma
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms22169039

Multiple Myeloma (MM) is a haematological disease resulting from the neoplastic transformation of plasma cells. The uncontrolled growth of plasma cells in the bone marrow and the delivery of several cytokines causes bone erosion that often does not regress, even in the event of disease remission. MM is characterised by a multi-step evolutionary path, which starts with an early asymptomatic stage defined as monoclonal gammopathy of undetermined significance (MGUS) evolving to overt disease.

alarmins cytokines multiple myeloma

1. Introduction

Multiple Myeloma (MM) is a haematological disease resulting from the neoplastic transformation of plasma cells, which are the terminally differentiated cells of the B lymphocyte line [1][2]. Malignant plasma cells can invade not only primarily the bone marrow but also peripheral blood and viscera in advanced widespread [3]. Plasma cells physiologically produce immunoglobulin (Ig). Malignant plasma cells produce and release excess monoclonal protein (M protein) in serum, which is also known as paraprotein [4]. The M protein will be excreted in the urine. Numerous genetic alterations favor the onset of the uncontrolled proliferation of plasma cells and the production of paraprotenin [1][2]. The uncontrolled growth of plasma cells in the bone marrow and the production of cytokines cause bone erosion, and the resulting bone lesions often do not regress, even in the event of disease remission. MM is the second most common haematological malignancy, and it is characterised by the appearance of bone pain, hypercalcemia, anemia, and renal failure [1][2][3]. MM is characterised by a multi-step evolutionary path, which starts with an early asymptomatic stage defined as monoclonal gammopathy of undetermined significance (MGUS) evolving to overt disease. MGUS is classified according to the secretion of Ig and, thus, into MGUS IgM and MGUS non-IgM. Although MGUS in most cases has a benign course, in some cases, it can evolve into aggressive forms. In particular, IgM MGUS can develop in Waldenström macroglobulinemia (WM) or, in fewer cases, in other non-Hodgkin’s lymphomas, while non-IgM MGUS originating from mature plasma cells can develop in MM [5]. MGUS can also secrete only the κ or λ light chain of Ig. Light chains aggregating are the cause of organ damage (i.e., heart, kidneys) both by depositing themselves or by favoring the deposition of amyloid from light chains (AL) [6][7]. However, in patients with MGUS, the M protein is <30 g/L and represents 20%–70% of all Ig, and circulating monoclonal plasma cells are <3 × 106 per liter [8]. The advent of new drugs such as proteasome inhibitors and immunomodulatory agents have certainly improved the prognosis and median overall survival of MM to over 60 months [9]. However, MM still remains an incurable disease. The clinical picture and its progression over time is favored and aggravated by the inevitable onset of drug resistance [10][11][12][13]. Plasma cell dysfunction and uncontrolled proliferation, granulocytopenia both from tumour marrow invasion and iatrogenic from chemotherapy, and high-dose administration of dexamethasone promote immunodeficiency in the patient with MM. Immunodeficiency favors both recurrent opportunistic infections and the evasion of the tumour from the immune response with its progression and wide spread [10][14][15][16][17]. Immunodeficiency is the consequence of both the weakening of B- and T-lymphocyte response, but also the antigen-presenting cells (APC); the natural killer (NK) cells are compromised in their number and functionality [10][18][19][20][21][22][23][24].
The previously reported alterations of the effectors of the immune system at the bone marrow level seem fundamental not only in the determinism of the disease but also in its progression. In MM, the crucial function of the BM tumour microenvironment and in particular in the effectors of the immune system contained therein is well recognised, and numerous reports have reported that plasma cells intensely depend on it [25]. MM plasma cells cooperate, directly and indirectly, with the bone marrow milieu stimulating growth, survival, and chemoresistance [26].
Moreover, a recent investigation revealed that in the BM, MM mesenchymal stem cells (MSCs) have a specific gene expression profile with respect to the normal MSCs. The evaluation of the gene co-expression network demonstrated that the principal altered activities in MM-MSCs are correlated to cell cycle progression and modifications of the immune response, which may participate in MM physiopathology [27].
Furthermore, several findings demonstrated that tumour progression in MM is linked to a change of tumour-specific immunity [28], proposing that immune surveillance may have an action in the prevention of MM disease evolution, as communications with the contiguous milieu are essential to MM cells’ survival [29]. BM immune effector interactions with plasma cells are essential for MM evolution, as contacts increase the generation of different anti-apoptotic and cell cycle-stimulating factors [30]. Plasma cells use numerous mechanisms to escape immune surveillance, which comprise modified interactions with T-cells, dendritic cells, and natural killer cells. These changes can be due to immunosuppressive cells and cytokines such as IL-10, TGFβ, and IL-6 as well as a reduction of the antigen processing machinery [31].

2. Role of the Immune System in MM Progression

The presence of T cells specific for the idiotype of the monoclonal paraprotein is described in patients with MGUS and MM, although there is still no definitive evidence on their actual role [32][33]. IL-1 plays a pivotal role in the progression from MGUS to MM as well as having a proinflammatory role. It is now well established that the plasma cells of patients with MM exhibit high concentrations of IL-1β. On the contrary, IL-1β is not detectable in the plasma cells of patients with MGUS. Therefore, the productive switch of IL-1β would represent a signal of malignant progression of the disease [34][35]. Confirming its probable role in the progression from MGUS to MM, IL-1β would seem to enhance the ability of plasma cells to cause lytic bone lesions, to induce the expression of adhesion molecules such as ICAM, CD44, CD54, CD56, CD44, and VLA-4 on plasma cells by increasing their capacity for transmigration and metastatic widespread [36][37][38][39][40]. It is hypothesised that a viral infection may represent the initial stimulus capable of inducing the upregulation of IL-1β. Among the viruses involved, there would be Kaposi’s sarcoma-associated herpesvirus, Epstein–Barr virus, human immunodeficiency virus-1, and respiratory syncytial virus [41][42]. An interesting finding that could give a further potential explanation of the cytokine network that favors disease progression would be related to the increased expression of IL-2R on MM cells and to a lesser extent on MGUS cells, suggesting that progression from MGUS to MM is also related to the alteration of the IL-2/IL-2R system [43].

3. Neoangiogenesis in MM

The elevated expression of HMGB1 has an undoubted role in the transformation of MGUS into MM and in the progression of MM itself, blocking cell apoptosis and inducing drug resistance by regulating the NF-κB signalling pathway. Notably, HMGB1 induces neoangiogenesis in patients with solid tumours and other hematological neoplasms. Meyer et al. [44] demonstrated in 18 non-Hodgkin lymphomas and two lymphoma cell lines that HMGB1 probably released from necrotic cells promotes tumour neoangiogenesis in a paracrine way. Zhan et al. [45] confirmed that autophagy induced the release of HMGB1 by gastric cancer cells into the extracellular space after exposure to vincristine, protecting gastric cancer cells from apoptosis through the upregulation of Mcl-1. Shrivastava et al. [46] demonstrated that elevated levels of HMGB1 reduced the response to radiotherapy in eight human urothelial carcinoma cell lines. Zhang et al. [47] confirmed HMGB1 expression in non-small cell lung cancer cell lines and that exposure to adriamycin, cisplatin, and methotrexate further increased HMGB1 levels. However, Chen et al. [48] confirmed the ability of HMGB1 to protect chronic myeloid leukemia cells from apoptosis, as proven in other studies [49][50][51][52]. Wu et al. [53] analysed the impact of HMGB1 expression on clinical progression in 166 patients with nasopharyngeal carcinoma. The study showed that the high expression of HMGB1 increased the risk of metastatic disease with poor prognosis. Süren et al. [54] confirmed the negative impact of HMGB1 in 110 patients with colorectal carcinoma. Several studies have shown that HMGB1 blockade restores apoptosis. It is plausible that HMGB1 promotes neoangiogenesis through the expression of vascular endothelial growth factor (VEGF) as occurs in chronic immune-mediated diseases and allergies such as allergic rhinitis [55][56]. Ostecytes play a key role in the progression of MM by promoting neoangiogenesis through the expression of molecules, including VEGF [57]. It is now shown that VEGF by stimulating its type 2 receptor (VEGFR2) induces neoangiogenesis, favoring the progression of MM [58]. Single nucleotide polymorphisms (SNPs) of VEGF and VEGFR2 genes have been demonstrated to play a key role in MM progression. For example, the presence of the VEGFR2-604TT genotype is associated with stage II or III tumours but not with stage I tumours [58]. Furthermore, endothelial dysfunction that accompanies neoangiogenesis in turn favors the passage of immune cells into the tumour environment through the expression of direct chemokines and cell adhesion molecules on the surface of endothelial cells as also occurs in chronic immune-mediated diseases [59][60].

4. Drug Resistance in MM

Crosstalk between adaptive immune cells and the endothelium is critical to tumour immune surveillance and the success of immune-based therapies that use immune cells to kill tumour cells. There are several factors that can reduce the pharmacological response of MM, resulting in disease progression. Notably, MicroRNAs (miRNAs) are an abundant group of endogenous non-coding RNAs (about 22 nt) binding to target mRNAs mainly at their 3′-untranslated (UTR) that displayed a key role in lung cancer [61]. However, miR-218 can inhibit the metastatic spread of tumours including non-small cell lung cancer and pancreatic cancer by blocking the expression of HMGB1 [62][63]. However, miRNAs appear to play a role in resistance to chemotherapy drugs. Ran et al. [64] demonstrated that the downregulation of miRNAs is associated with resistance to paclitaxel in endometrial cancer cells. Notably, miR-218 binds directly to the 3’-UTR of the HMGB1 gene, the upregulation of which induces resistance to paclitaxel in endometrial cancer cells by promoting autophagy. MiR-218 overexpression would inhibit HMGB1-induced autophagy by restoring tumour cell response to paclitaxel.

5. MGUS to MM: Role of Immunoglobulin Chains

The roles that the quantity and type of M protein and the ratio of free immunoglobulin chains have in the evolution of the disease from MGUS to MM is now widely accredited. It is also evident that the suppression of the production of PIg is not only a progression factor but also has a negative impact on the clinical evolution favoring “immune paresis” and consequently increasing the risk of opportunistic infections [65][66]. Rapid progression from MGUS to MM is favored by the decreased synthesis of IgM in subjects with IgG or IgA gammopathy, and of IgA in individuals with IgG or IgM gammopathy [67][68][69]. The network that influences immune paresis is certainly complex, and it is not yet completely clear whether it all starts from the dysregulation of cytokines and whether this dysregulation is due to defects in immune surveillance, the proliferation of clonal plasma cells, or opportunistic infections [70]. Moreover, the immune paresis reaches its peak with old age but decreases among the very elderly [71]. HMGB1 facilitates autophagy by disrupting the interaction between Beclin 1 and its downregulator Bcl2 via competitively binding to Beclin 1 [72]. Wang et al. confirmed that increased HMGB1 expression in the neuroblastoma NB SH-SY5Y cell line induced resistance to treatment with doxorubicin, etoposide, and cisplatin. Sensitivity to treatment was restored after HMGB1 was knocked out by RNA interference [54]. HMGB1 has been shown to induce elevated levels of LC3-II (a protein light chain associated with microtubules that plays a role in autophagosome formation) and the selective degradation of p62 (a ubiquitin-related protein) in autophagy. In this way, the green fluorescent protein-light chain 3 favors the generation of autophagosomes [54].

6. HMGB1/RAGE Axis as Crosstalking between Immune Cells and Bone Tissue

In patients with pancreatic cancer, the mechanism of action of HMGB1 is not yet fully understood, although it seems to have a dual action. It is likely to inhibit tumourigenesis by stabilising the genome through its direct binding to p53 at the intracellular level and by binding to certain receptors including RAGE, TLR-2, TLR-4, and TLR-9 as well as by interacting with cytokines and growth factors at the extracellular level [55]. In patients with MM, a plant-based chemical lycorine has been shown to be able to decrease HMGB1 and, therefore, LC3 and Beclin-1, thereby blocking autophagy. In particular, lycorin dissociates Bcl2 from Beclin-1 by acting through the ubiquitin–proteasome pathway [72]. Lycorin restores the response of MM patients to bortezomib treatment by reducing HMGB1 expression. These data confirm that lycorine has a dual activity: both antitumourigenic and promoting sensitisation to chemotherapy in MM [73]. There is no doubt that the not too distant future approach will be to design and synthesise monoclonal antibodies directed against specific molecules including HMGB1 to make therapies targeted and hopefully with fewer adverse effects [74]. Confirming this, Usman et al. [75] have reported some clinical trials targeting HMGB1. RAGE is among the receptors to which HMGB1 binds, and it is a member of the immunoglobulin superfamily and is a transmembrane receptor that binds to AGE. HMGB1 activates RAGE or activates the peroxisome via the proliferator-activated receptor gamma (PPAR-γ) with consequent inhibition of the HMGB1-RAGE axis, and this mechanism could also represent a future therapeutic strategy beneficial against tumours [76][77]. Furthermore, CXCR4 expression is ubiquitous in different hematopoietic cells [78], and its role in the evolution of MM has already been demonstrated [79]. It is now well established that elevated levels of CXCR4, integrins (i.e., CD11a/CD11c/CD29/CD49d/CD49e), and adhesion molecules (i.e., CD44/CD54) in patients with MM induce resistance to chemotherapy [80][81]. Furthermore, the HMGB1/RAGE axis has now been shown to be able to favor bone loss. HMGB1 is expressed in primary osteoblasts and osteoclasts both expressing RAGE. Furthermore, the RANKL/osteoprotegerin (OPG)/receptor activator of NF-κB (RANK) signalling axis plays a critical role in DCs function as well as bone remodeling. RANKL is present in DCs that release HMGB1 and represents a mode of crosstalking between immune cells and bone tissue. These data would confirm the complexity of the mechanisms and the role of the bone marrow microenvironment in the progression of MM [82][83]. RAGE is encoded in the Class III region of the major histocompatibility complex and it is the multiligand receptor of the immunoglobulin superfamily. RAGE stimulated by AGEs has been shown to trigger pro-tumourigenic pathways by promoting the dissemination of melanoma and pancreatic cancer cells [83] and probably has a similar action also in colorectal, oesophageal, and oral squamous cell carcinoma, since in these tumours, it is upregulated and, therefore, acts as an oncoprotein [55][56]. The fact that levels of sRAGE are higher in the IgA Lambda MM, which has a poorer prognosis, is explained as a reactive mechanism to the tumour, which is fully confirmed by the ability of the same sRAGE to bind other ligands such as proinflammatory molecules. There is no doubt that HSPs also play a role in the activation of proinflammatory cytokines secreted by monocytes/macrophages and favor the activation of immature DCs [60][84]. IL6 increases the expression of HSP90 in patients with MM, thus favoring the survival of myelomatous plasma cells. It is now shown that the increase in HSP90 levels is induced by STAT3 and CCAAT/enhancer-binding protein β (C⁄EBPβ), which bind to and activate the HSP90β promoter [85]. In Figure 1 the researchers have summarized the crosstalking between immune cells and bone tissue in multiple myeloma.
Figure 1. Crosstalking between immune cells and bone tissue in multiple myeloma.

7. Mutational Status, Inflammation, and MM Progression

Similar to all tumours, MM is a condition caused by genetic alterations capable of both inducing the disease and influencing its prognosis. It remains to be assessed whether even in MM the inflammatory condition may be able to determine a particular mutational state capable of favoring the disease or whether genetic mutations of MM can affect an inflammatory condition. For instance, a characteristic of myelodysplastic syndromes (MDSs) is stimulation of the NLRP3 inflammasome, which provokes clonal proliferation and pyroptotic cell death. MDS hematopoietic stem cells overexpress inflammasome proteins that direct the generation of interleukin-1β, IL-18, and pyroptotic cell death. Mechanistically, pyroptosis is triggered by the alarmin S100A9 that is found in excess in MDS HSPCs and BM plasma. Further, similar to somatic gene mutations, S100A9-induced signalling activates NADPH oxidase (NOX), increasing levels of reactive oxygen species (ROS) that initiate cation influx, cell swelling, and β-catenin activation. Notably, the knockdown of NLRP3 or caspase-1, neutralisation of S100A9, and pharmacologic inhibition of NLRP3 or NOX suppress pyroptosis, ROS production, and nuclear β-catenin in MDSs and are sufficient to restore effective hematopoiesis. Thus, alarmins and founder gene mutations in MDSs license a common redox-sensitive inflammasome circuit, which proposes new approaches for therapeutic intervention [86].
Similarly, transcriptomic studies of hematopoietic stem cells from patients affected by myeloproliferative neoplasms (MPNs) with driver mutations have established the upregulation of inflammation-related genes able to cause the development of an inflammatory state. The possibility of operating on the inflammatory state as a therapeutic approach in MPNs appears promising, in which an intervention acting on the pathways that control the synthesis of cytokines and oxidative stress could be successful in decreasing the possibility of leukemic progression [87].
As far as the relationship between immune response, inflammation, and mutational status, MM subjects with the same genetic alterations are inclined to have both plasma cells and immune cells clustered together [88].
Numerous genomic analyses have led to a better understanding of the molecular pathogenesis of myeloma. These reports have verified recurrent mutations in KRAS, NRAS, and TP53 as well as a significant percentage of previously unknown mutations influencing RNA processing and protein homeostasis [89].
In a study, Liu et al. validated AP-1 complex differential expression (JUN and FOS) in plasma cell subpopulations using mass cytometry (CyTOF)-based protein assays. Integrated analysis of single-cell RNA and CyTOF data revealed activator-protein-1 (AP-1) downstream targets (IL6 and IL1B) potentially leading to inflammation regulation. Thus, the close link between gene alterations, immune response, and inflammation in MM is further highlighted [90].
Furthermore, as far the role of alarmins in MM progression and the possibility of their use as biomarkers to predict MGUS evolution or disease relapse in patients, a recent report indicated that a significant augmented risk for being diagnosed with MGUS was linked to inflammatory disorders, while inflammatory signalling has a central role in MSC transformation by causing a pro-tumour phenotype correlated with a permissive BM milieu permitting immune escape and MM growth [91].
Finally, Botta et al. investigated the relevance of inflammatory genes in predicting disease evolution and patient survival. They performed a bioinformatics study on a gene expression profiling dataset of MGUS, smoldering MM, and symptomatic MM, and they recognised inflammatory and cytokine/chemokine pathways as the most gradually modified during disease evolution. They identified an eight-gene signature (IL8, IL10, IL17A, CCL3, CCL5, VEGFA, EBI3, and NOS2), distinguishing each condition (MGUS/smoldering/symptomatic MM) with 84% accuracy. Moreover, six genes (IFNG, IL2, LTA, CCL2, VEGFA, CCL3) were reported independently correlated with patient survival. Subjects whose MM cells presented high concentrations of Th1 cytokines (IFNG/LTA/IL2/CCL2) experienced the longest survival. On these genes, they developed a prognostic risk score. In this study, they furnished a proof that inflammation has an essential effect in MM patient progression and survival. The inflammatory gene prognostic signature evidently suggests new prospects for personalised anti-MM therapy [92].
Similar studies performed on alarmins will definitively clarify the possibility of using these molecules as biomarkers and prognostic factors in monoclonal gammopathies.

References

  1. Rollig, C.; Knop, S.; Bornhauser, M. Multiple myeloma. Lancet 2015, 385, 2197–2208.
  2. Kunacheewa, C.; Orlowski, R.Z. New drugs in multiple myeloma. Annu. Rev. Med. 2019, 70, 521–547.
  3. Kumar, S.K.; Rajkumar, V.; Kyle, R.A.; Van Duin, M.; Sonneveld, P.; Mateos, M.V.; Gay, F.; Anderson, K.C. Multiple myeloma. Nat. Rev. Dis. Primers 2017, 3, 17046.
  4. Legarda, M.A.; Cejalvo, M.J.; De La Rubia, J. Recent Advances in the Treatment of Patients with Multiple Myeloma. Cancers 2020, 12, 3576.
  5. Kyle, R.A.; Benson, J.; Larson, D.; Therneau, T.; Dispenzieri, A.; Melton Iii, L.J.; Rajkumar, S.V. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström’s macroglobulinemia. Clin. Lymphoma Myeloma 2009, 9, 17–18.
  6. Dispenzieri, A.; Katzmann, J.A.; Kyle, R.A.; Larson, D.R.; Melton, L.J., 3rd; Colby, C.L.; Therneau, T.M.; Clark, R.; Kumar, S.K.; Bradwell, A.; et al. Prevalence and risk of progression of light-chain monoclonal gammo-pathy of undetermined significance: A retrospective population-based cohort study. Lancet 2010, 375, 1721–1728.
  7. Marinac, C.R.; Ghobrial, I.M.; Birmann, B.; Soiffer, J.; Rebbeck, T.R. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020, 10, 1–8.
  8. Weiss, B.M.; Abadie, J.; Verma, P.; Howard, R.S.; Kuehl, W.M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113, 5418–5422.
  9. Kumar, S.K.; Callander, N.S.; Alsina, M.; Atanackovic, D.; Biermann, J.S.; Castillo, J.; Chandler, J.C.; Costello, C.; Faiman, M.; Fung, H.C. NCCN Guidelines Insights: Multiple Myeloma, Version 3. J. Natl. Compr. Cancer Netw. 2018, 16, 11–20.
  10. Tamura, H. Immunopathogenesis and immunotherapy of multiple myeloma. Int. J. Hematol. 2018, 107, 278–285.
  11. Nikesitch, N.; Ling, S.C.W. Molecular mechanisms in multiple myeloma drug resistance. J. Clin. Pathol. 2015, 69, 97–101.
  12. Jahangir, A.; Chen, G.; Hong, C. Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mech-anisms. Oncotarget 2013, 4, 2186.
  13. González, D.; Van Der Burg, M.; Garcia-Sanz, R.; Fenton, J.A.; Langerak, A.W.; González, M.; Van Dongen, J.; Miguel, J.S.; Morgan, G. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007, 110, 3112–3121.
  14. Kiertscher, S.M.; Luo, J.; Dubinett, S.M.; Roth, M.D. Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells. J. Immunol. 2000, 164, 1269–1276.
  15. Greil, R.; Egle, A.; Villunger, A. On the Role and Significance of Fas (Apo-1/CD95) Ligand (FasL) Expression in Immune Privileged Tissues and Cancer Cells Using Multiple Myeloma as a Model. Leuk. Lymphoma 1998, 31, 477–490.
  16. Brown, R.D.; Murray, A.; Pope, B.; Sze, D.M.; Gibson, J.; Ho, P.J.; Hart, D.N.; Joshua, D. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β 1 in patients with myeloma. Br. J. Haematol. 2004, 125, 743–748.
  17. Villunger, A.; Egle, A.; Marschitz, I.; Kos, M.; Böck, G.; Ludwig, H.; Geley, S.; Kofler, R.; Greil, R. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune sur-veillance. Blood 1997, 90, 12–20.
  18. Yoneda, K.-I.; Morii, T.; Nieda, M.; Tsukaguchi, N.; Amano, I.; Tanaka, H.; Yagi, H.; Narita, N.; Kimura, H. The peripheral blood Vα24+NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk. Res. 2005, 29, 147–152.
  19. Koike, M.; Sekigawa, I.; Okada, M.; Matsumoto, M.; Iida, N.; Hashimoto, H.; Oshimi, K. Relationship between CD4+/CD8+ T cell ratio and T cell activation in multiple myeloma: Reference to IL-16. Leuk. Res. 2002, 26, 705–711.
  20. Ogawara, H.; Handa, H.; Yamazaki, T.; Toda, T.; Yoshida, K.; Nishimoto, N.; Al-Ma’Quol, W.H.S.; Kaneko, Y.; Matsushima, T.; Tsukamoto, N.; et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk. Res. 2005, 29, 135–140.
  21. MacGregor, R.R.; Negendank, W.G.; Schreiber, A.D. Impaired granulocyte adherence in multiple myeloma: Relationship to complement system, granulocyte delivery, and infection. Blood 1978, 51, 591–599.
  22. Mills, K.H.G.; Cawley, J.C. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple mye-loma: Relationship to treatment and clinical stage. Br. J. Haematol. 1983, 53, 271–275.
  23. Rawstron, A.C.; Davies, F.E.; Owen, R.G.; English, A.; Pratt, G.; Child, J.A.; Jack, A.S.; Morgan, G.J. B-lymphocyte suppres-sion in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br. J. Haematol. 1998, 100, 176–183.
  24. Hájek, R.; Butch, A.W. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol. 2000, 17, 2–15.
  25. Mitsiades, C.S.; Mitsiades, N.S.; Munshi, N.C.; Richardson, P.G.; Anderson, K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 2006, 42, 1564–1573.
  26. Caers, J.; Van Valckenborgh, E.; Menu, E.; Van Camp, B.; Vanderkerken, K. Unraveling the biology of multiple myeloma disease: Cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 2008, 95.
  27. Fernando, R.C.; Mazzotti, D.R.; Azevedo, H.; Sandes, A.F.; Gil Rizzatti, E.; De Oliveira, M.B.; Alves, V.L.F.; Eugênio, A.I.P.; De Carvalho, F.; Dalboni, M.A.; et al. Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism. Sci. Rep. 2019, 9, 1–16.
  28. Spisek, R.; Kukreja, A.; Chen, L.-C.; Matthews, P.; Mazumder, A.; Vesole, D.; Jagannath, S.; Zebroski, H.A.; Simpson, A.J.; Ritter, G.; et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 2007, 204, 831–840.
  29. Song, G.; Darr, D.B.; Santos, C.M.; Ross, M.; Valdivia, A.; Jordan, J.L.; Midkiff, B.R.; Cohen, S.; Nikolaishvili-Feinberg, N.; Miller, C.; et al. Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. Clin. Cancer Res. 2014, 20, 6083–6095.
  30. Manier, S.; Sacco, A.; Leleu, X.; Ghobrial, I.M.; Roccaro, A.M. Bone Marrow Microenvironment in Multiple Myeloma Progression. J. Biomed. Biotechnol. 2012, 2012, 1–5.
  31. Lee, S.J.; Borrello, I. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma. Immunotoxins 2016, 169, 207–225.
  32. Yi, Q.; Osterborg, A. Idiotype-specific T cells in multiple myeloma: Targets for an immunotherapeutic intervention? Med. On-col. 1996, 13, 1–7.
  33. Yi, Q.; Osterborg, A.; Bergenbrant, S.; Mellstedt, H.; Holm, G.; Lefvert, A.K. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995, 86, 3043–3049.
  34. Cozzolino, F.; Torcia, M.; Aldinucci, D.; Rubartelli, A.; Miliani, A.; Shaw, A.R.; Lansdorp, P.M.; Di Guglielmo, R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989, 74, 380–387.
  35. Donovan, K.; Lacy, M.; Kline, M.; Ahmann, G.; Heimbach, J.; Kyle, R.; Lust, J. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia 1998, 12, 593–600.
  36. Hawley, T.S.; Lach, B.; Burns, B.F.; May, L.T.; Sehgal, P.B. Hawley RG. Expression of retrovirally transduced IL-1 alpha in IL-6-dependent B cells: A murine model of aggressive multiple myeloma. Growth Factors 1991, 5, 327–338.
  37. Hawley, R.G.; Wang, M.H.; Fong, A.Z.; Hawley, T.S. Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas. Clin. Exp. Metastasis 1993, 11, 213–226.
  38. Van Camp, B.; Durie, B.G.; Spier, C.; De Waele, M.; Van Riet, I.; Vela, E.; Frutiger, Y.; Richter, L.; Grogan, T.M. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990, 76, 377–382.
  39. Lewinsohn, D.M.; Nagler, A.; Ginzton, N.; Greenberg, P.; Butcher, E.C. Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood 1990, 75, 589–595.
  40. Drach, J.; Gattringer, C.; Huber, H. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin. Exp. Immunol. 1991, 83, 418–422.
  41. Corley, P. Induction of interleukin-1 and glucocorticoid hormones by HIV promotes viral replication and links human chromosome 2 to AIDS pathogenesis: Genetic mechanisms and therapeutic implications. Med. Hypotheses 1997, 48, 415–421.
  42. Beaulieu, A.D.; Paquin, R.; Gosselin, J. Epstein-Barr virus modulates de novo protein synthesis in human neutrophils. Blood 1995, 86, 2789–2798.
  43. Bitko, V.; Velazquez, A.; Yang, L.; Yang, Y.C.; Barik, S. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology 1997, 232, 369–378.
  44. Vacca, A.; Di Stefano, R.; Frassanito, A.; Iodice, G.; Dammacco, F. A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin. Exp. Immunol. 1991, 84, 429–434.
  45. Meyer, A.; Staratschek-Jox, A.; Springwald, A.; Wenk, H.; Wolf, J.; Wickenhauser, C.; Bullerdiek, J. Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk. Lymphoma 2008, 49, 1184–1189.
  46. Zhan, Z.; Li, Q.; Wu, P.; Ye, Y.; Tseng, H.Y.; Zhang, L.; Zhang, X.D. Autophagymediated HMGB1 release antagonizes apop-tosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy 2012, 8, 109–121.
  47. Shrivastava, S.; Mansure, J.J.; Almajed, W.; Cury, F.; Ferbeyre, G.; Popovic, M.; Seuntjens, J.; Kassouf, W. The Role of HMGB1 in Radioresistance of Bladder Cancer. Mol. Cancer Ther. 2016, 15, 471–479.
  48. Zhang, R.; Li, Y.; Wang, Z.; Chen, L.; Dong, X.; Nie, X. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Tumor Biol. 2015, 36, 8585–8592.
  49. Chen, X.; Wang, Y.; Liu, J.; Xu, P.; Zhang, X.-M.; Tian, Y.-Y.; Xue, Y.-M.; Gao, X.-Y.; Liu, Y.; Wang, J.-H. Synergistic effect of HMGB1 knockdown and cordycepin in the K562 human chronic myeloid leukemia cell line. Mol. Med. Rep. 2015, 12, 4462–4468.
  50. Tang, D.; Kang, R.; Livesey, K.M.; Cheh, C.-W.; Farkas, A.; Loughran, P.; Hoppe, G.; Bianchi, M.E.; Tracey, K.J.; Zeh, H.J.; et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 2010, 190, 881–892.
  51. Roy, M.; Liang, L.; Xiao, X.; Peng, Y.; Luo, Y.; Zhou, W.; Zhang, J.; Qiu, L.; Zhang, S.; Liu, F.; et al. Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma. Theranostics 2016, 6, 2209.
  52. Cebrián, M.J.G.; Bauden, M.; Andersson, R.; Holdenrieder, S.; Ansari, D. Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter? Anticancer Res. 2016, 36, 4381–4390.
  53. Wang, L.; Zhang, H.; Sun, M.; Yin, Z.; Qian, J. High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance. Oncol. Rep. 2015, 34, 2969–2976.
  54. Wu, D.; Ding, Y.; Wang, S.; Zhang, Q.; Liu, L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J. Pathol. 2008, 216, 167–175.
  55. Sezer, C.; Süren, D.; Yıldırım, M.; Demirpençe, O.; Kaya, V.; Alikanoğlu, A.S.; Bülbüller, N.; Yıldız, M. The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer. Med. Sci. Monit. 2014, 20, 530–537.
  56. Biscetti, F.; Flex, A.; Pecorini, G.; Angelini, F.; Arena, V.; Stigliano, E.; Gremese, E.; Tolusso, B.; Ferraccioli, G. The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. Clin. Exp. Immunol. 2016, 184, 62–72.
  57. Ciprandi, G.; Murdaca, G.; Colombo, B.M.; De Amici, M.; Marseglia, G.L. Serum vascular endothelial growth factor in aller-gic rhinitis and systemic lupus erythematosus. Hum. Immunol. 2008, 69, 510–512.
  58. Mulcrone, P.L.; Edwards, S.K.E.; Petrusca, D.N.; Haneline, L.S.; Delgado-Calle, J.; Roodman, G.D. Osteocyte Vegf-a contrib-utes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci. Rep. 2020, 10, 17319.
  59. Brito, A.B.; Lourenço, G.J.; Oliveira, G.B.; De Souza, C.A.; Vassallo, J.; Lima, C.S. Associations of VEGF and VEGFR2 poly-morphisms with increased risk and aggressiveness of multiple myeloma. Ann. Hematol. 2014, 93, 1363–1369.
  60. Murdaca, G.; Colombo, B.M.; Cagnati, P.; Gulli, R.; Spanò, F.; Puppo, F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224, 309–317.
  61. Solimando, A.G.; De Summa, S.; Vacca, A.; Ribatti, D. Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers 2020, 12, 3380.
  62. Murdaca, G.; Tonacci, A.; Negrini, S.; Greco, M.; Borro, M.; Puppo, F.; Gangemi, S. Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models. Int. J. Mol. Sci. 2019, 20, 3938.
  63. Zhang, C.; Ge, S.; Hu, C.; Yang, N.; Zhang, J. MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim. Biophys. Sin. 2013, 45, 1055–1061.
  64. Liu, Z.; Xu, Y.; Long, J.; Guo, K.; Ge, C.; Du, R. microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1. Chin. J. Cancer Res. 2015, 27, 247–257.
  65. Allegra, A.; Innao, V.; Allegra, A.G.; Pugliese, M.; Di Salvo, E.; Ventura-Spagnolo, E.; Musolino, C.; Gangemi, S. Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Int. J. Mol. Sci. 2019, 20, 2822.
  66. Musolino, C.; Allegra, A.; Innao, V.; Allegra, A.G.; Pioggia, G.; Gangemi, S. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediat. Inflamm. 2017, 2017, 1–24.
  67. Ran, X.; Yang, J.; Liu, C.; Zhou, P.; Xiao, L.; Zhang, K. MiR-218 inhibits HMGB1-mediated autophagy in endometrial carci-noma cells during chemotherapy. Int. J. Clin. Exp. Pathol. 2015, 8, 6617–6626.
  68. Pika, T.; Lochman, P.; Sandecka, V.; Maisnar, V.; Minarik, J.; Tichy, M.; Zapletalova, J.; Solcova, L.; Scudla, V.; Hajek, R. Immunoparesis in MGUS—Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. Neoplasma 2015, 62, 827–832.
  69. Magnano, L.; Fernández de Larrea, C.; Elena, M.; Cibeira, M.T.; Tovar, N.; Aróstegui, J.I.; Pedrosa, F.; Rosiñol, L.; Filella, X.; Yagüe, J.; et al. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients with Monoclonal Gammopathy of Unde-termined Significance and Smoldering Myeloma: Long-Term Results from a Single Institution. Clin. Lymphoma Myeloma Leuk. 2016, 16, e71–e77.
  70. Valković, T.; Gačić, V.; Ivandić, J.; Petrov, B.; Dobrila-Dintinjana, R.; Dadić-Hero, E.; Načinović-Duletić, A. Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors. Turk J. Haematol. 2015, 32, 234–242.
  71. Cherry, B.M.; Costello, R.; Zingone, A.; Burris, J.; Korde, N.; Manasanch, E.; Kwok, M.; Annunziata, C.; Roschewski, M.; Engels, E.A.; et al. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. Am. J. Hematol. 2012, 88, 89–92.
  72. Fu, L.-L.; Cheng, Y.; Liu, B. Beclin-1: Autophagic regulator and therapeutic target in cancer. Int. J. Biochem. Cell Biol. 2013, 45, 921–924.
  73. Li, Y.; Liu, J.; Tang, L.-J.; Shi, Y.-W.; Ren, W.; Hu, W.-X. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest. Oncol. Rep. 2007, 17, 377–384.
  74. Takahashi, H.; Nishibori, M. Current status and future prospects in HMGB1 and receptor researches. Nihon Rinsho. Jpn. J. Clin. Med. 2016, 74, 703–711.
  75. Usman, R.M.; Razzaq, F.; Akbar, A.; Farooqui, A.A.; Iftikhar, A.; Latif, A.; Hassan, H.; Zhao, J.; Carew, J.S.; Nawrocki, S.T.; et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia-Pac. J. Clin. Oncol. 2020, 17, 193–208.
  76. Galliera, E.; Marazzi, M.G.; Vianello, E.; Drago, L.; Luzzati, A.; Bendinelli, P.; Maroni, P.; Tacchini, L.; Desiderio, M.A.; Romanelli, M.M.C. Circulating sRAGE in the diagnosis of osteolytic bone metastasis. J. Biol. Regul. Homeost. Agents 2016, 30, 1203–1208.
  77. Huang, L.; Wang, Y.; Bai, J.; Yang, Y.; Wang, F.; Feng, Y.; Zhang, R.; Li, F.; Zhang, P.; Lv, N.; et al. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. Cell Stress Chaperon 2020, 25, 357–367.
  78. Chatterjee, S.; Azad, B.B.; Nimmagadda, S. The Intricate Role of CXCR4 in Cancer. Adv. Cancer Res. 2014, 124, 31–82.
  79. Coniglio, S.J. Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis. Front. Endocrinol. 2018, 9.
  80. Paiva, B.; Corchete, L.A.; Vidriales, M.B.; Puig, N.; Maiso, P.; Rodriguez, I.; Alignani, D.; Burgos, L.; Sanchez, M.L.; Barcena, P.; et al. Spanish Myeloma Group/Program for the Study of Malignant Blood Diseases Therapeutics (GEM/PETHEMA) Cooperative Study Groups. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to under-stand chemoresistance. Blood 2016, 127, 1896–1906.
  81. Ullah, T.R. The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond. J. Bone Oncol. 2019, 17, 100253.
  82. Charoonpatrapong, K.; Shah, R.; Robling, A.G.; Alvarez, M.; Clapp, D.W.; Chen, S.; Kopp, R.; Pavalko, F.M.; Yu, J.; Bidwell, J.P. HMGB1 expression and release by bone cells. J. Cell. Physiol. 2006, 207, 480–490.
  83. Ishibashi, Y.; Matsui, T.; Takeuchi, M.; Yamagishi, S. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated pro-tein kinase. Horm. Metab. Res. 2013, 45, 387–390.
  84. Temajo, N.O.; Howard, N. The virus-induced HSPs regulate the apoptosis of operatus APCs that results in autoimmunity, not in homeostasis. Autoimmun. Rev. 2014, 13, 1013–1019.
  85. Takagi, S.; Tsukamoto, S.; Park, J.; Johnson, K.E.; Kawano, Y.; Moschetta, M.; Liu, C.J.; Mishima, Y.; Kokubun, K.; Manier, S.; et al. Platelets Enhance Multiple My-eloma Progression via IL-1β Upregulation. Clin. Cancer Res. 2018, 24, 2430–2439.
  86. Basiorka, A.A.; McGraw, K.L.; Eksioglu, E.A.; Chen, X.; Johnson, J.; Zhang, L.; Zhang, Q.; Irvine, B.A.; Cluzeau, T.; Sallman, D.A.; et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 2016, 128, 2960–2975.
  87. Allegra, A.; Pioggia, G.; Tonacci, A.; Casciaro, M.; Musolino, C.; Gangemi, S. Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR-ABL-Negative Myeloproliferative Neoplasm. Antioxidants 2020, 9, 1037.
  88. Liu, R.; Gao, Q.; Foltz, S.M.; Fowles, J.S.; Yao, L.; Wang, J.T.; Cao, S.; Sun, H.; Wendl, M.C.; Sethuraman, S.; et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat. Commun. 2021, 12, 1–18.
  89. Walker, B.; Boyle, E.M.; Wardell, C.; Murison, A.; Begum, D.B.; Dahir, N.M.; Proszek, P.Z.; Johnson, D.C.; Kaiser, M.F.; Melchor, L.; et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients with Newly Diagnosed Myeloma. J. Clin. Oncol. 2015, 33, 3911–3920.
  90. Castaneda-Avila, M.A.; Ulbricht, C.M.; Epstein, M.M. Risk factors for monoclonal gammopathy of undetermined significance: A systematic review. Ann. Hematol. 2021, 100, 855–863.
  91. Giallongo, C.; Tibullo, D.; Camiolo, G.; Parrinello, N.L.; Romano, A.; Puglisi, F.; Barbato, A.; Conticello, C.; Lupo, G.; Anfuso, C.D.; et al. TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. Cell Death Dis. 2019, 10, 704–714.
  92. Botta, C.; DI Martino, M.T.; Ciliberto, D.; Cucè, M.; Correale, P.; Rossi, M.; Tagliaferri, P.; Tassone, P. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J. 2016, 6, e511.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Hematology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Giuseppe Murdaca
,
Alessandro Allegra
,
Francesca Paladin
,
Fabrizio Calapai
,
Caterina Musolino
,
Sebastiano Gangemi
View Times: 226
Revisions: 2 times (View History)
Update Date: 01 Aug 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback